Induction of t lymphocytes specific to human gastric cancer using hla-a matched allogeneic gastric tumor cells

Journal of Immunotherapy

Volumn 26, Issue 5, 2003, Pages 403-411

  Nie, Yongzhan ^a   Wu, Kaichun ^a   Yang, Jinghua ^a   Tian, Fengqi ^a   Li, Ling ^b   Chen, Baojun ^b   Fan, Daiming ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cytotoxic T lymphocyte; HLA; Immunotherapy; Stomach

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FLOW CYTOMETRY; HLA MATCHING; HUMAN; HUMAN CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STOMACH CANCER; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD8; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; RABBITS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0141818353     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200309000-00003     Document Type: Article

References (50)

1. Heidecker L, Brasseur F, Probst-Kepper M, et al. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol. 2000; 164:6041-6045.
2. Ren-Heidenreich L, Lum LG. Life or death of T cells with antigen-specific receptors—using T cells for cancer adoptive immunotherapy/gene therapy. Curr Gene Ther. 2001; 1:253-255.
3. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989; 57:503-512.
4. Waanders GA, Rimoldi D, Lienard D, et al. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin Cancer Res. 1997; 3:685-696.
5. Brouwenstijn N, Hoogstraten C, Verdegaal EM, et al. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma. J Immunother. 1998; 21:427-434.
6. Osanto S, Schiphorst PP, Weijl NI, et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2producing melanoma cell line. Hum Gene Ther. 2000; 11:739-750.
7. Wu KC, Jackson LM, Galvin AM, et al. Phenotypic and functional characterisation of myofibroblasts, macrophages, and lymphocytes migrating out of the human gastric lamina propria following the loss of epithelial cells. Gut. 1999; 44:323-330.
8. Yasoshima T, Sato N, Hirata K, et al. The mechanism of human autologous gastric signet ring cell tumor rejection by cytotoxic T lymphocytes in the possible context of HLA-A31 molecule. Cancer. 1995; 75:1484-1489.
9. Nabeta Y, Sahara H, Suzuki K, et al. Induction of cytotoxic T lymphocytes from peripheral blood of human histocompatibility antigen (HLA)-A31(+) gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma. Jpn J Cancer Res. 2000; 91:616-621.
10. Shimizu Y, Weidmann E, Iwatsuki S, et al. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res. 1991; 51:6153-6162.
11. Kono K, Rongcun Y, Charo J, et al. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer. 1998; 78:202-208.
12. Kono K, Ichihara F, Iizuka H, et al. Differences in the recognition of tumor-specific CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer. Int J Cancer. 1997; 71:978-981.
13. Stevens EJ, Jacknin L, Robbins PF, et al. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J Immunol. 1995; 154:762-771.
14. Yang S, Darrow TL, Seigler HF. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. Cancer Res. 1997; 57:1561-1568.
15. Arienti F, Sule-Suso J, Belli F, et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther. 1996; 7:1955-1963.
16. Buhmann R, Nolte A, Westhaus D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999; 93:1992-2002.
17. Verdegaal EM, Huinink DB, Hoogstraten C, et al. Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999; 60:1195-1206.
18. Shawler DL, Bartholomew RM, Garrett MA, et al. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin Exp Immunol. 2002; 129:99-106.
19. Chardon P, Kirszenbaum M, Cullen PR, et al. Analysis of the sheep MHC using HLA class I, II, and C4 cDNA probes. Immunogenetics. 1985; 22:349-358.
20. Geertsen R, Boni R, Blasczyk R, et al. Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations. Int J Cancer. 2002; 99:82-87.
21. Browning MJ, Krausa P, Rowan A, et al. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA. 1993; 90:2842-2845.
22. Kuzushima K, Nakamura S, Nakamura T, et al. Increased frequency of antigen-specific CD8(+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. J Clin Invest. 1999; 104:163-171.
23. Anderson PM, Ochoa AC, Ramsay NK, et al. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity. Blood. 1992; 80:1846-1853.
24. Rebai N, Malissen B. Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. Tissue Antigens. 1983; 22:107-117.
25. Torsteinsdottir S, Brautbar C, Klein G, et al. Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells? Int J Cancer. 1988; 41:913-919.
26. Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999; 80:92-97.
27. Roche PW, Feng CG, Britton WJ. Human T-cell epitopes on the Mycobacterium tuberculosis secreted protein MPT64. Scand J Immunol. 1996; 43:662-670.
28. Noppen C, Levy F, Burri L, et al. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer. 2000; 87:241-246.
29. Linehan DC, Goedegebuure PS, Peoples GE, et al. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol. 1995; 155:4486-4491.
30. Peiper M, Goedegebuure PS, Izbicki JR, et al. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Anticancer Res. 1999; 19:2471-2475.
31. Romphruk A, Burusrux S, Puapairoj C, et al. Distribution of HLA-A and B antigens in northeastern-Thais. J Med Assoc Thai. 1996; 79:732-736.
32. Kanno H, Kojya S, Li T, et al. Low frequency of HLA-A*0201 allele in patients with Epstein-Barr virus-positive nasal lymphomas with polymorphic reticulosis morphology. Int J Cancer. 2000; 87:195-199.
33. Koyama S, Maruyama T, Adachi S, et al. Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J Cancer Res Clin Oncol. 1998; 124:383-388.
34. Chan AK, Goedegebuure PS, von Bernstorff W, et al. B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable alpha and beta genes of the T- cell receptor. Surgery. 2000; 127:342-350.
35. Crowley NJ, Darrow TL, Seigler HF. Generation of autologous tumor-specific cytotoxic T-cells using HLA-A region matched allogeneic melanoma. Curr Surg. 1989; 46:393-396.
36. Fearon ER, Itaya T, Hunt B, et al. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 1988; 48:2975-2980.
37. Blankenstein T, Qin ZH, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med. 1991; 173:1047-1052.
38. Abdel-Wahab Z, Dar M, Osanto S, et al. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Ther. 1997; 4:33-41.
39. Anderson BW, Peoples GE, Murray JL, et al. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res. 2000; 6:4192-4200.
40. Mortarini R, Borri A, Tragni G, et al. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res. 2000; 60:3559-3568.
41. Anichini A, Molla A, Mortarini R, et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med. 1999; 190:651-667.
42. Montagna D, Locatelli F, Calcaterra V, et al. Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study. Bone Marrow Transplant. 1998; 22:743-750.
43. Christ O, Matzku S, Burger C, et al. Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo. Clin Cancer Res. 2001; 7:1385-1397.
44. Ley V, Roth C, Langlade-Demoyen P, et al. A novel approach to the induction of specific cytolytic T cells in vivo. Res Immunol. 1990; 141:855-863.
45. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999; 190:705-715.
46. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998; 58:4902-4908.
47. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000; 96:3102-3108.
48. Pascolo S, Schirle M, Guckel B, et al. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 2001; 61:4072-4077.
49. Ofuji S, Ikeda M, Tsujitani S, et al. Expression of MAGE-1, MAGE-2 and MAGE-3 genes in human gastric carcinomas; lack of evidence for cytotoxic effects in cases with simultaneous expression of MAGE-3 and HLA-A2. Anticancer Res. 1998; 18:3639-3644.
50. Hinoda Y, Takahashi T, Hayashi T, et al. Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells. J Gastroenterol. 1998; 33:164-171.